Nájar Ana M, López Azcárate Cristina, Domínguez Ruiz Carmen, Núñez-Jurado David, de Torres Reyes, López Reyes, Camino-Moya Miriam, Magni Eleonora, Montero-Ramirez Emilio, Bocero Antonio, Laviana Álvaro, Busquier Cerdán Teresa, León Antonio, Del Rio Carmen, Montaner Joan, Pérez-Sánchez Soledad
Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen Macarena/CSIC/Universidad de Sevilla, 41013 Seville, Spain.
Department of Biochemistry, Hospital Universitario Virgen Macarena, 41009 Seville, Spain.
Nutrients. 2024 Dec 13;16(24):4307. doi: 10.3390/nu16244307.
Transient ischemic attack (TIA) is a well-established risk factor for future strokes, making interventions that target recovery and vascular risk crucial. This study aimed to assess the safety and clinical effects of a polyphenol-rich extract in post-TIA patients. A randomized, triple-blind, placebo-controlled trial was conducted with participants who had a history of TIA or minor stroke and who received 1 g of Salicornia extract or placebo over 11 months. Biochemical analyses, neuropsychological assessments (MOCA test), and gait and aerobic performance tests were conducted at the beginning and the end of the study. A total of 118 individuals were screened, with 80 finally included. Importantly, no significant adverse events were reported throughout the study. A neurological analysis showed an improvement in MOCA scores in patients treated with the Salicornia extract for 11 months. The treatment did not affect spatiotemporal gait parameters, but it significantly reduced blood pressure at baseline and after the aerobic performance test. Biochemically, both groups exhibited mild hyperhomocysteinemia at baseline; however, Salicornia treatment significantly lowered homocysteine levels, bringing them within the normal range. These findings highlight the safety of the Salicornia extract in patients at a high cerebrovascular risk and suggest it as a potential therapeutic option for managing vascular risk factors, such as hyperhomocysteinemia and hypertension. However, further studies are required to confirm the underlying mechanisms and explore broader clinical applications.
短暂性脑缺血发作（TIA）是未来中风的一个公认危险因素，因此针对恢复和血管风险的干预措施至关重要。本研究旨在评估富含多酚的提取物对TIA后患者的安全性和临床效果。对有TIA或轻度中风病史的参与者进行了一项随机、三盲、安慰剂对照试验，这些参与者在11个月内接受了1克盐角草提取物或安慰剂。在研究开始和结束时进行了生化分析、神经心理学评估（蒙特利尔认知评估测试）以及步态和有氧运动能力测试。共筛查了118人，最终纳入80人。重要的是，整个研究过程中未报告重大不良事件。神经学分析显示，接受盐角草提取物治疗11个月的患者蒙特利尔认知评估测试得分有所提高。该治疗对时空步态参数没有影响，但在基线时和有氧运动能力测试后显著降低了血压。在生化方面，两组在基线时均表现出轻度高同型半胱氨酸血症；然而，盐角草治疗显著降低了同型半胱氨酸水平，使其降至正常范围内。这些发现突出了盐角草提取物在高脑血管风险患者中的安全性，并表明它是管理血管危险因素（如同型半胱氨酸血症和高血压）的一种潜在治疗选择。然而，需要进一步研究来证实其潜在机制并探索更广泛的临床应用。
